Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duligotuzumab vs Cetuximab with FOLFIRI in KRAS wt mCRC
NCT01652482Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2012
- Primary completion
- Nov 2014
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of duligotuzumab in metastatic colorectal cancer (mCRC), sponsored by Genentech. Started Oct 2012; status: completed.
02
Drugs
duligotuzumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01652482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652482.